Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Authors:
- Kenichi HaranoKHKenichi Harano
- Takehiro NakaoTNTakehiro Nakao
- Shin NishioShin Nishio
- Takahiro KatsudaTKTakahiro Katsuda
- Kazuto TasakiKTKazuto Tasaki
- Kazuhiro TakeharaKTKazuhiro Takehara
- Takanori YokoyamaTYTakanori Yokoyama
- Hideki FuruyaHFHideki Furuya
- Kyoko HongoKHKyoko Hongo
- Masatoshi AsanoMAMasatoshi Asano
- Takashi IkenoTITakashi Ikeno
- Masashi WakabayashiMWMasashi Wakabayashi
- 30 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4580-4591
Abstract
Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results: The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions: Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.Keywords
All Related Versions
Funding Information
- Merck (58918)
- Merck
This publication has 47 references indexed in Scilit:
- Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 StudyInternational Journal of Gynecological Cancer, 2025
- LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)Annals of Oncology, 2024
- Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsCell, 2024
- Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)Gynecologic Oncology, 2023
- Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerEuropean Journal of Cancer, 2023
- Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study (041)Gynecologic Oncology, 2022
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyThe Lancet Oncology, 2021
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian CancerJAMA Oncology, 2019
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerCell Reports, 2018